QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   905.86 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.65 (+0.59%)
BABA   72.43 (+1.17%)
T   17.66 (+0.63%)
F   13.19 (+1.00%)
MU   117.66 (-1.24%)
CGC   9.64 (+0.94%)
GE   174.80 (-2.95%)
DIS   122.61 (+1.35%)
AMC   3.69 (-14.98%)
PFE   28.01 (+0.83%)
PYPL   67.21 (+0.96%)
XOM   115.91 (+0.82%)
NASDAQ:LABP

Landos Biopharma (LABP) Stock Price, News & Analysis

$21.36
0.00 (0.00%)
(As of 01:08 PM ET)
Today's Range
$21.35
$21.87
50-Day Range
$4.55
$21.56
52-Week Range
$2.50
$21.87
Volume
42,450 shs
Average Volume
21,999 shs
Market Capitalization
$66.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Landos Biopharma MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.28mentions of Landos Biopharma in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.03) to ($1.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.41 out of 5 stars

Medical Sector

901st out of 939 stocks

Pharmaceutical Preparations Industry

414th out of 433 stocks

LABP stock logo

About Landos Biopharma Stock (NASDAQ:LABP)

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

LABP Stock Price History

LABP Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Leerink Partners Remains a Hold on Landos Biopharma (LABP)
AbbVie To Acquire Landos Biopharma At $20.42/share In Cash
AbbVie to buy Landos Biopharma for $137 million
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Why Is Landos Biopharma (LABP) Stock Up 168% Today?
Recap: Landos Biopharma Q4 Earnings
Xontogeny, LLC's Net Worth
See More Headlines
Receive LABP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Landos Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/12/2023
Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LABP
Fax
N/A
Employees
19
Year Founded
N/A

Profitability

Net Income
$-21,930,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$18 million
Book Value
$10.20 per share

Miscellaneous

Free Float
3,076,000
Market Cap
$66.64 million
Optionable
Not Optionable
Beta
-0.41
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Gregory Oakes (Age 56)
    President, CEO & Director
    Comp: $1.04M
  • Mr. Timothy M. Mayleben M.B.A. (Age 63)
    Principal Financial Officer & Director
    Comp: $555.99k
  • Dr. Fabio Cataldi M.D. (Age 57)
    Executive VP & Chief Medical Officer
    Comp: $516.68k
  • Ms. Rebecca Mosig Ph.D.
    Vice President of Corporate Development
  • Dr. Josep Bassaganya-Riera DVM (Age 49)
    Ph.D., Advisor
    Comp: $1.79M

LABP Stock Analysis - Frequently Asked Questions

How have LABP shares performed in 2024?

Landos Biopharma's stock was trading at $3.66 at the start of the year. Since then, LABP stock has increased by 483.6% and is now trading at $21.36.
View the best growth stocks for 2024 here
.

When is Landos Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our LABP earnings forecast
.

How were Landos Biopharma's earnings last quarter?

Landos Biopharma, Inc. (NASDAQ:LABP) released its quarterly earnings results on Friday, May, 12th. The company reported ($0.90) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.10.

When did Landos Biopharma's stock split?

Shares of Landos Biopharma reverse split on the morning of Friday, May 26th 2023. The 1-10 reverse split was announced on Friday, May 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Landos Biopharma IPO?

Landos Biopharma (LABP) raised $101 million in an initial public offering on Thursday, February 4th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Raymond James was co-manager.

How do I buy shares of Landos Biopharma?

Shares of LABP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LABP) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners